171 related articles for article (PubMed ID: 18070706)
1. New insights into the biology and advances in the management of multiple myeloma.
Harousseau JL
Best Pract Res Clin Haematol; 2007 Dec; 20(4):569-70. PubMed ID: 18070706
[No Abstract] [Full Text] [Related]
2. Stem cell transplantation for multiple myeloma: current status and future directions.
Caldera H; Giralt S
Curr Hematol Rep; 2004 Jul; 3(4):249-56. PubMed ID: 15217554
[TBL] [Abstract][Full Text] [Related]
3. Pro: allogeneic transplantation in multiple myeloma.
Gahrton G
Clin Adv Hematol Oncol; 2006 May; 4(5):388-91. PubMed ID: 16728947
[No Abstract] [Full Text] [Related]
4. Transplantation for multiple myeloma: who, when, how often? Patient selection and goals.
Vesole DH
Blood; 2003 Nov; 102(10):3471-2. PubMed ID: 14658424
[No Abstract] [Full Text] [Related]
5. Multiple myeloma: new aspects of biology and treatment.
Ozaki S; Kosaka M
J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
[TBL] [Abstract][Full Text] [Related]
6. Role of autologous stem-cell transplantation in multiple myeloma.
Attal M; Harousseau JL
Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem-cell transplantation for myeloma: it's time for the appropriate studies.
Gratwohl A
J Clin Oncol; 2011 Jun; 29(16):e483; author reply e484. PubMed ID: 21464404
[No Abstract] [Full Text] [Related]
8. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of combining ATRA with G-CSF in HSPC mobilization; a pilot study in multiple myeloma and non-Hodgkin's lymphoma patients.
Herbert KE; True S; McArthur G; Prince HM
Bone Marrow Transplant; 2007 Oct; 40(8):801-3. PubMed ID: 17680017
[No Abstract] [Full Text] [Related]
10. Allografting or autografting for myeloma.
Moreau P; Harousseau JL; Attal M
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600892
[No Abstract] [Full Text] [Related]
11. High-dose therapy in multiple myeloma.
Bladé J; Vesole DH; Gertz Morie
Blood; 2003 Nov; 102(10):3469-70. PubMed ID: 12893762
[No Abstract] [Full Text] [Related]
12. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
[No Abstract] [Full Text] [Related]
13. Stem cell transplantation in multiple myeloma.
Björkstrand B
Hematology; 2005; 10 Suppl 1():26-8. PubMed ID: 16188627
[No Abstract] [Full Text] [Related]
14. Pretransplant induction regimens for multiple myeloma.
Vesole DH; Siegel DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):200-1. PubMed ID: 25534538
[No Abstract] [Full Text] [Related]
15. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Braiteh F; Hymes SR; Giralt SA; Jones R
J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
[No Abstract] [Full Text] [Related]
16. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in multiple myeloma.
Tricot G
Clin Adv Hematol Oncol; 2005 Mar; 3(3):167-8. PubMed ID: 16166987
[No Abstract] [Full Text] [Related]
18. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
[TBL] [Abstract][Full Text] [Related]
19. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
20. Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.
Cook G
Bone Marrow Transplant; 2015 Oct; 50(10):1269-70. PubMed ID: 26237169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
